The French Speciality Pharmaceutical Company, Juvisé Pharmaceuticals Acquires Two Oncology Products From AstraZeneca in Over 40 Countries
The French speciality pharmaceutical company, Juvisé Pharmaceuticals is pleased to announce the successful completion of a transaction with AstraZeneca, regarding the acquisition of the commercial rights of Arimidex® (anastrozole ) and Casodex® (bicalutamide ) in a number of European, African and other countries.
This first transaction of Juvisé Pharmaceuticals with AstraZeneca is a logical next step after multiple worldwide deals accomplished by the French company with several other big pharmaceutical companies over the past years.
With this acquisition, Juvisé Pharmaceuticals enters the oncology therapeutic area, in which the company wants to further expand and consolidates its fast-growing ambition.
Frédéric Mascha, Founder and President of Juvisé Pharmaceuticals, declared “we are very pleased to have successfully closed our first deal with AstraZeneca and to enter a therapeutic area with high medical needs such as oncology with Arimidex® and Casodex®, which are two widely recognized cancer treatments essential for both patients and physicians”.
Arimidex® (anastrozole ) is an aromatase inhibitor, indicated primarily for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer, the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer and the treatment of advanced breast cancer in postmenopausal women with disease progression, following tamoxifen therapy.
Casodex® (bicalutamide ) is an androgen-receptor inhibitor, indicated for use in combination therapy with a luteinising hormone-releasing hormone analogue for the treatment of Stage D2 metastatic carcinoma of the prostate.
About Juvisé Pharmaceuticals
Juvisé Pharmaceuticals is an international pharmaceutical company, specialized in manufacturing and commercializing ethical original drugs with high medical value for patients suffering from cardiovascular, oncology or neuro-psychiatric diseases.
11 years after its creation, Juvisé Pharmaceuticals has become a recognized international company commercializing its own drugs in 75 countries around the word.
For more information, please visit juvisepharmaceuticals.com .
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MA-HIGHRES24.1.2020 15:02:08 CET | Press release
HighRes Biosolutions and Novo Nordisk partner to transform drug discovery in automated Lab of the Future
CONQUEST24.1.2020 13:39:04 CET | Press release
Conquest Invests in 5 Greenfield Onshore Wind Parks Totalizing 43MW in the Flanders Region
TX-FLUENCE24.1.2020 12:02:09 CET | Press release
Fluence Expands EMEA Footprint with Horticulture Partners in Papenburg, Germany
HCL-TECHNOLOGIES24.1.2020 10:49:07 CET | Press release
HCL Technologies Honors Global Goodwill Champions at the 2020 World Economic Forum in Davos
IPSEN24.1.2020 07:02:06 CET | Press release
Ipsen’s palovarotene clinical program in fibrodysplasia ossificans progressiva reaches prespecified interim analysis futility criteria
AMAZENTIS23.1.2020 21:58:10 CET | Press release
Amazentis Announces the Launch of Timeline™ Cellular Nutrition at the World Economic Forum in Davos
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom